Analyst Upgrades

• BB&T (BBT) was upgraded to buy from neutral at Janney Montgomery.
• Amylin (AMLN) was upgraded to outperform from market perform at Leerink.
• Wells Fargo upgraded Morton's Restaurant (MRT) to outperform from market perform.
• Check Point (CHKP) was upgraded to overweight from neutral at HSBC.
• Deutsche Bank upgraded Excel Maritime (EXM) to buy from hold.
• JinkoSolar (JKS) was upgraded to buy from hold at Auriga.
• Piper Jaffray upgraded Compellent (CML) to overweight from neutral.
• BofA/Merrill upgraded Crane (CR) to buy from neutral.
• Goldman upgraded Wisconsin Energy (WEC) to conviction buy from buy and American Electric (AEP) to buy from neutral.
• Motorola (MOT) was upgraded due to increasing carrier support by MKM Partners.
• Under Armour (UA) was upgraded to buy from neutral at Sterne Agee.

Investors took yesterday's drop as an opportunity. The new consensus is that the double-dip recession scenario is gone and that quantitative easing will also still occur. The dollar gave back on some of yesterday's gains, and that helped gold and oil and related assets. Then the Fed's Beige Book acted like a "economic upgrade" from the Fed.

Here were today's unofficial closing bell levels:

DJIA
NASDAQ
S&P500

Top Analyst Calls

Analyst Upgrades

• Citigroup upgraded Mosaic (MOS) to buy from hold and raised its price target to $78 from $64 citing improving ag fundamentals and the potential for BHP (BHP) to issue a higher bid for Potash (POT), which Citi feels would bode well for Mosaic.
• Cowen upgraded VMware (VMW) to outperform from neutral, citing recent share weakness and the company's significant growth opportunity.
• Citigroup upgraded CareFusion (CFN) with a $29 price target, citing valuation and the potential for margin expansion.
• Pfizer (PFE) was upgraded to outperform from neutral at Cowen.
• Juniper (JNPR) was upgraded to outperform from perform at Oppenheimer.
• Stryker (SYK) was upgraded to buy from gradually accumulate at Soleil.

Analyst Upgrades

• SunTrust upgraded Lennox (LII) to buy from neutral, given signs of improved residential HVAC equipment and service demand and a bottom in commercial lines. The firm has a $55 price target on the stock.
• Cowen upgraded Universal Display (PANL) to outperform from neutral. The firm expects OLED display growth to accelerate driven by increased handset and other mobile device penetration, followed by high-end TV and lighting applications.
• Canaccord upgraded Amylin (AMLN) to hold from sell following Roche's (RHHBY) delay in its Phase 3 study for taspo, a competitor to Amylin's bydureon. The firm has an $18 target on Amylin shares.
• DiamondRock Hospitality (DRH) was upgraded to buy from hold at Citigroup.
• Public Service (PEG) was upgraded to conviction buy from buy at Goldman.
• QuinStreet (QNST) was upgraded to overweight on valuation at Thomas Weisel.

Analyst Upgrades

• Keefe Bruyette upgraded East West Bancorp (EWBC) to outperform from market perform after the company acquired assets from Washington First International Bank. The firm has a $21 price target for shares.
• Piper Jaffray upgraded Amylin (AMLN) to overweight from neutral, citing valuation and Bydureon's profile. The firm maintains a $26 price target for shares.
• Soleil upgraded MGM Mirage (MGM) to hold from sell, citing signs of stabilization in Vegas and valuation. The firm upped its target for shares to $13 from $11.10.
• T. Rowe Price (TROW) was upgraded to outperform from market perform at FBR Capital.
• JetBlue (JBLU) was upgraded to buy from neutral at BofA/Merrill.
• NetEase.com (NTES) was upgraded to buy from hold at Standpoint Research.

Analyst Upgrades

• Stephens upgraded Schlumberger (SLB) to overweight from equal weight with an $80 price target, citing valuation and the company's international activity.
• Roth Capital upgraded Synutra International (SYUT) to buy from hold, citing the company's improved outlook, increased market share and valuation. The firm has a $27 target on shares.
• Oppenheimer upgraded Progressive (PGR) to perform from underperform as it believes the company's focus on growth could move shares higher in the near-term.
• Inergy Holdings (NRGP) was upgraded to buy from hold at Wunderlich.
• Best Buy (BBY) was upgraded to hold from sell at Societe Generale.
• Vale SA (VALE) was upgraded to buy from hold at Canaccord.

Analyst Upgrades

• UBS upgraded Dr Pepper Snapple (DPS) to buy from neutral, citing strong fundamentals and buybacks. The firm raised its target to $42 from $31.
• Piper Jaffray upgraded ProAssurance (PRA) to overweight from neutral. The firm has a $76 price target on shares.
• Hershey (HSY) and Sunoco (SUN) were upgraded to sell from conviction sell at Goldman.
• Level 3 Comm (LVLT) was upgraded to neutral from underweight at JPMorgan.
• Cathay Pacific (CPCAY) was upgraded to buy from hold at Deutsche Bank.

Analyst Upgrades

• UBS upgraded Boeing (BA) to neutral from sell, citing increased delivery forecasts. The firm raised its target to $68 from $50.
• Benchmark Co. upgraded Meredith Corp. (MDP) to buy from hold to reflect improving broadcasting and magazine advertising fundamentals. The firm raised its target for shares to $40 from $36.
• Keefe Bruyette upgraded Transatlantic (TRH) to market perform from underperform after the annual statutory data was published. The firm raised its target for shares to $51 from $4.
• Disney (DIS) was upgraded to buy from neutral at BofA/Merrill.
• Royal Caribbean (RCL) was upgraded to neutral from sell at Goldman.
• FedEx (FDX) was upgraded to outperform from market perform at Morgan Keegan.

Analyst Upgrades

• Barrington upgraded Lincoln Electric (LECO) to outperform from market perform to reflect its positive 2010-2012 outlook for the global welding sector. The firm has a $60 price target on shares.
• Merriman upgraded Akamai (AKAM) to buy from neutral as it believes the company's market share losses have stemmed and traffic volume growth should outpace pricing declines.
• Oppenheimer upgraded Blackstone Group (BX) to outperform from perform, citing improving fundamentals and disclosure. The firm set a $20.50 price target on the stock.
  
• Freeport McMoRan (FCX) was upgraded to outperform from sector perform at RBC Capital.
• Charles River Labs (CRL) was upgraded to equal weight from underweight at Morgan Stanley.
  

Analyst Upgrades

• Jefferies upgraded Citrix Systems (CTXS) to buy from hold and raised its target to $48 from $43, citing VMware's (VMW) strong Q4 report and survey results that indicate continued strength for Citrix.
• Citigroup upgraded Amylin Pharmaceuticals (AMLN) to buy from hold on confidence the company's LAR drug will be approved following the approval of Novo Nordisk's (NVO) Victoza. Citi raised its target price for Amylin shares to $27 from $4.
• Baird upgraded Texas Instruments (TXN) to outperform from neutral and raised its target to $30 from $28. The firm believes it is too early to take profits in Texas Instruments and notes that checks continue to indicate a continued recovery in end-demand.
• Lexmark (LXK) was upgraded to overweight from equal weight at Barclays.
• Salix (SLXP) was upgraded to outperform from perform at Oppenheimer.
• Plexus (PLXS) was lifted to outperform from neutral at Credit Suisse.

Analyst upgrades:

• Wells Fargo upgraded Prudential (PRU) to outperform from market perform. The firm thinks the company is in a better position than its peers and will be able to more effectively exploit M&A opportunities.
• UBS upgraded Reliance Steel (RS) to buy from neutral based on potential growth through M&A and valuation. The firm raised its target to $50 from $49.
• Deutsche Bank upgraded Eastman Chemical (EMN) to buy from hold on expectations the company's portfolio transformation will drive higher normalized earnings power, which the firm believes is not fully reflected in consensus estimates. Deutsche raised its target price on shares to $70 from $62.
• Amylin Pharma (AMLN) was upgraded to overweight from equal weight at Barclays.
• Cephalon (CEPH) was upgraded to buy from hold at Jefferies.
• Acuity Brands (AYI) was upgraded to outperform from perform at Oppenheimer.

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) caught an early morning boost after reporting positive results from its obesity drug trials. A mid-stage study of its pramlintide/metreleptin combination product revealed no significant side effects on a cardiovascular or neuropsychiatric level, and patients treated with the highest dose experienced much greater weight loss than those participants treated with a placebo.

AMLN was up more than 2% at its intraday peak, but the equity has since pulled back near the break-even line. The stock settled Wednesday below its 20-day moving average for the first time in more than a month, and it has been unable today to reclaim a foothold above this trendline. Meanwhile, stubborn resistance from the $14 region looms not far overhead.

Analyst upgrades:

• Deutsche Bank upgraded Portland General Electric (NYSE: POR) to Buy from Hold on valuation as it finds the risk/reward on shares attractive at current levels. The firm raised its target price to $22 from $20.
  
• FBR Capital upgraded Abercrombie & Fitch (NYSE: ANF) to Outperform from Market Perform after channel checks indicated recent sales are driving increased traffic and easing market share losses. The firm raised its target price on shares to $37 from $21.
• Barclays upgraded Yahoo (NASDAQ: YHOO) to Overweight from Equal Weight as it believes the company is well positioned for a rebound in advertising and that the valuation is compelling at current levels. The firm raised its target on shares to $20 from $15.
• Kohl's (NYSE: KSS) was raised to Overweight from Market Weight at Thomas Weisel.
  
• U.S. Steel (NYSE: X) and CB Richard Ellis (NYSE: CBG) were upgraded at Goldman to Neutral from Sell.
  
• Dolby Laboratories (NYSE: DLB) was upgraded at JP Morgan to Overweight from Neutral.

Analyst upgrades:

• Morgan Stanley said Bank of America's (NYSE: BAC) capital needs are largely known and shares are trading "cheaply despite reduced downside risk." The firm upgraded shares to Overweight from Underweight and raised the price target to $25 from $16. Shares were also upgraded to Outperform from Neutral at Baird citing manageable capital needs and attractive risk/reward.
  
• Keefe Bruyette upgraded Fifth Third Bancorp (NASDAQ: FITB) to Outperform from Market Perform on valuation as it views the stock as inexpensive despite the recent rally. The firm has an $8 target on the stock.
• Banc of America/Merrill upgraded Ericsson (NASDAQ: ERIC) to Buy from Neutral as it believes fewer hedging losses could bring upside over the next few quarters.
• Rio Tinto (NYSE: RTP) was raised to Overweight from Neutral at Barclays.
  
• EnerNOC (NASDAQ: ENOC) was lifted to Buy from Neutral at Janney Montgomery.
  
• Westpac Banking (NYSE: WBK) was upgraded to Neutral from Underperform at Credit Suisse.

Stocks fell today as financials were hit hard after a report from UBS predicted losses in the banking sector again in 2009. Jamie Dimon's interview comments didn't give any massive confidence boost either. This was the first day that there was a major move to the upside in what feels like forever, as oil was up $3.49 per barrel at $47.01 on last look. Today's weekly jobless claims data was also the worst we have seen in this part of the cycle.

Here are today's closing bell levels:
DJIA: 8,565.09 (-2.24)
S&P 500: 873.58 (-2.85)
NASDAQ: 1,507.88 (-3.68)

52-Week Lows

Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) announced that the US FDA gave feedback on the DURATION-1 study for once/week diabetes treatment that will allow it to file a new drug application later in the first half of 2009. Shares were up 19% at $10.18 right before the close.

Costco Wholesale Corp. (NASDAQ: COST) beat earnings with $0.65 EPS vs. $0.62 estimates. Revenues were a tad light. The company said its sales were hurt by a slowdown in non-food discretionary sales and related reductions in margins associated with these sales in the latter half of the quarter.